3-Benzyloxy-2-methyl-4-pyridone | 267416-92-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Benzyloxy-2-methyl-4-pyridone
• 英文别名: 2-methyl-3-phenylmethoxy-3H-pyridin-4-one
• CAS: 267416-92-2
• 化学式: C₁₃H₁₃NO₂
• 分子量: 215.25
• InChiKey: CIYMSCIMEZGJEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Benzyloxy-2-methyl-4-pyridone 、 乙酰溴 、 三乙胺 在 二氯甲烷 、 盐酸 、 水 、 Sodium sulfate-III 、 ethyl acetate n-hexane 作用下， 以 丙酮 为溶剂， 反应 16.0h， 以gives 1-acetyl-3-benzyloxy-2-methylpyrid-4-one as an oil (3.1 g)的产率得到1-乙酰基-2-甲基-3-苯基甲氧基吡啶-4-酮
  参考文献：
  名称：

  Pharmaceutical compositions

  摘要：

  含有3-羟基吡啶-2-酮或3-羟基吡啶，其中连接氮原子的氢原子被取代为脂肪族酰基团、脂肪族碳氢基团或被一个或一个以上的取代基取代，所述取代基选自脂肪族酰基、烷氧基、脂肪族胺、脂肪族酰胺、羧基、脂肪族酯、卤素、羟基和磺酸基，但不包括仅被脂肪族碳氢基团取代的化合物，或其盐，其中包含生理上可接受的离子，对于从体内去除有毒量的金属，特别是铁，具有价值。

  公开号：

  USRE035948E1
• 作为产物：
  描述：

  氨 、 3-(苄氧基)-2-甲基-4H-吡喃-4-酮 在 乙酸乙酯 作用下， 以 乙醇 为溶剂， 反应 120.0h， 以to give 32.2 g of 3-benzyloxy-2-methyl-4-pyridone as a light yellow crystal的产率得到3-Benzyloxy-2-methyl-4-pyridone
  参考文献：
  名称：

  Picolinamide derivative and harmful organism control agent comprising said picolinamide derivative as active component

  摘要：

  本发明揭示了一种用于控制有害生物的新化合物，使用该化合物的有害生物控制剂以及制备该新化合物的方法。本发明中有用的新化合物包括由式（1）表示的化合物。式（1）表示的化合物对有害生物具有强效活性，并且不对农业和园艺植物产生植物毒性，作为本发明中应用于预防和灭除目的的对象，以及人类和动物。其中，A表示键或可选取代的烷基链；R1表示一个或多个基团，可以是相同或不同的，选自氢原子，烷氧基和卤代烷氧基；R2表示氢原子，苄基，烷基或烷酰基，其中除氢原子外的基团可以被取代；R3表示氢原子，环烷基，环烯基，芳基或杂环基，其中除氢原子外的基团可以被取代，但当R1表示氢原子，A表示键或亚甲基链，R3表示苯基或环己基时，以及当A表示烷基链，R3表示氢原子时，排除上述情况。

  公开号：

  US07183278B1

文献信息

• [EN] DESFERRITHIOCIN ANALOGS AND USES THEREOF<br/>[FR] ANALOGUES DE LA DESFERRITHIOCINE ET LEURS UTILISATIONS
  申请人：UNIV FLORIDA

  公开号：WO2015077655A1

  公开（公告）日：2015-05-28

  Iron overload is associated with pathological conditions such as oxidative stress, transfusional iron overload, thalassemia, primary hemochromatosis, secondary hemochromatosis, diabetes, liver disease, heart disease, cancer, radiation injury, neurological or neurodegenerative disorder, Friedreich's ataxia (FRDA), macular degeneration, closed head injury, irritable bowel disease, and reperfusion injury. The present invention provides methods and pharmaceutical compositions using desferrithiocin analogs of Formulae (A) and (J) for treating and/or preventing these pathological conditions, metal (e.g., iron, aluminum, a lanthanide, or an actinide (e.g., uranium)) overload conditions, and infectious diseases (e.g., malaria).

  铁过载与病理条件相关，如氧化应激、输血性铁过载、地中海贫血、原发性血色病、继发性血色病、糖尿病、肝病、心脏病、癌症、放射损伤、神经或神经退行性疾病、弗里德雷希共济失调（FRDA）、黄斑变性、闭合性头部损伤、肠易激综合征和再灌注损伤。本发明提供使用式（A）和（J）的去铁胱醇类似物的方法和药物组合物，用于治疗和/或预防这些病理条件、金属（如铁、铝、镧系元素或锕系元素（如铀））过载症状和传染病（如疟疾）。
• Iron-pyridone complexes for anemia
  申请人：National Research Development Corporation

  公开号：US04650793A1

  公开（公告）日：1987-03-17

  Pharmaceutical compositions containing an iron complex of a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionizable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by aliphatic hydrocarbon groups, are of value for the treatment of iron deficiency anemia.

  含有3-羟基吡啶-2-酮或3-羟基吡啶-4-酮的铁络合物的药物组合物，其中氮原子上连接的氢原子被取代为脂肪族酰基团、脂肪族碳氢基团或被选自脂肪族酰基、烷氧基、脂肪族胺、脂肪族酰胺、羧基、脂肪族酯、卤素、羟基和磺酸基中的一个或一个以上取代基的烷基碳氢基团取代，且可选地，其中一个或多个连接到环碳原子的氢原子被取代为上述取代基之一，或被取代为烷氧基、脂肪族酯、卤素或羟基的脂肪族碳氢基团或被取代为烷氧基、脂肪族酯、卤素或羟基的脂肪族碳氢基团取代，但不包括仅由脂肪族碳氢基团取代化合物的价值，用于治疗缺铁性贫血。
• Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases
  申请人：Hanauske-Abel M. Hartmut

  公开号：US20050288187A1

  公开（公告）日：2005-12-29

  The present invention is directed to a method of inhibiting 4-hydroxyphenylpyruvate dioxygenase in a living system by administering to the living system an effective amount of a compound of formulas I or II or III or derivatives thereof as follows: R 1 , R 2 , R 3 , and R 4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms under conditions effective to inhibit 4-hydroxyphenylpyruvate dioxygenase in the living system. These compounds are also useful in carrying out a method of treating a patient and a method of regulating plant growth.

  本发明涉及通过向生物体内投与式I或II或III或其衍生物的有效量来抑制生物体内4-羟基苯丙酮酸双氧酶的方法，其中：R1，R2，R3和R4分别表示氢，含1至约8个碳原子的烷基，烯基或烷氧基，含约5至12个碳原子的芳基，芳基烷基或环烷基，含多达8个碳原子的羧基烷氧基或氨基甲酰基，或含有10至约30个碳原子的肽或类肽基团，在有效条件下抑制生物体内的4-羟基苯丙酮酸双氧酶。这些化合物还可用于进行治疗患者的方法和调节植物生长的方法。
• Iron III complexes of hydroxypyridones, and their pharmaceutical compositions
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0120670A1

  公开（公告）日：1984-10-03

  Pharmaceutical compositions containing an iron complex of a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionisable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by aliphatic hydrocarbon groups, are of value for the treatment of iron deficiency anaemia.

  含有 3-羟基吡啶-2-酮或 3-羟基吡啶-4-酮铁络合物的药物组合物，其中与氮原子相连的氢原子被脂肪族酰基、脂肪族烃基或被一个或一个以上取代基取代的脂肪族烃基所取代（可电离基团除外），取代基选自脂肪族酰基、烷氧基、脂肪族胺、脂肪族酰胺、羧基、脂肪族酯、卤素、在可离子化基团的情况下，一个以上选自脂肪族酰基、烷氧基、脂肪族酰胺、羧基、脂肪族酯、卤素、羟基和磺基的取代基，以及环碳原子上的一个或多个氢原子被上述取代基、脂肪族烃基或被烷氧基、脂肪族酯、卤素或羟基取代的脂肪族烃基取代，但不包括化合物中的氢原子仅被脂肪族烃基取代的化合物，这些化合物具有治疗缺铁性贫血的价值。
• Hydroxypyridones, and their pharmaceutical compositions
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0120669A2

  公开（公告）日：1984-10-03

  Pharmaceutical compositions containing a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionisable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by aliphatic hydrocarbon groups, or a saltthereof containing a physiologically acceptable ion or ions, are of value for removing toxic amounts of metals, particularly iron, from the body.

  含有 3-羟基吡啶-2-酮或 3-羟基吡啶-4-酮的药物组合物，其中与氮原子相连的氢原子被脂族酰基、脂族烃基取代、或被一个或一个以上取代基取代的脂肪族烃基，这些取代基选自脂肪族酰基、烷氧基、脂肪族胺、脂肪族酰胺、羧基、脂肪族酯、卤素、羟基和亚砜基，可选的情况除外、其中与环碳原子相连的一个或多个氢原子被上述取代基之一、脂肪族烃基或被烷氧基、脂肪族酯、卤素或羟基取代的脂肪族烃基所取代，但不包括化合物中的氢原子仅被脂肪族烃基取代的化合物，或含有生理上可接受的一种或多种离子的盐。